Država: Kanada
Jezik: angleščina
Source: Health Canada
RAMIPRIL; HYDROCHLOROTHIAZIDE
BAUSCH HEALTH, CANADA INC.
C09BA05
RAMIPRIL AND DIURETICS
2.5MG; 12.5MG
TABLET
RAMIPRIL 2.5MG; HYDROCHLOROTHIAZIDE 12.5MG
ORAL
15G/50G
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0251649002; AHFS:
APPROVED
2021-03-03
_Pr_ _ALTACE _ _®_ _ HCT (Ramipril and Hydrochlorothiazide Tablets) Product Monograph Page 1 of 65_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR ALTACE ® HCT Ramipril and hydrochlorothiazide Tablets Tablets, 2.5/12.5 mg, 5/12.5 mg, 10/12.5 mg, 5/25 mg, 10/25 mg, Oral Angiotensin Converting Enzyme Inhibitor Plus Diuretic Bausch Health, Canada Inc. 2150 St-Elzear Blvd. West Laval, Quebec H7L 4A8 Date of Initial Authorization: April 23, 2015 Date of Revision: January 6, 2023 Submission Control Number: 265837 _ _ _Pr_ _ALTACE _ _®_ _ HCT (Ramipril and Hydrochlorothiazide Tablets) Product Monograph Page 2 of 65_ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Ophthalmologic 06/2021 7 WARNINGS AND PRECAUTIONS, Respiratory 01/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .................................................................................... 2 TABLE OF CONTENTS ......................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION.............................................................. 4 1 INDICATIONS............................................................................................................. 4 1.1 Pediatrics .......................................................................................................... 4 1.2 Geriatrics........................................................................................................... 4 2 CONTRAINDICATIONS .............................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX..................................................... 5 4 DOSAGE AND ADMINISTRATION ............................................................................. 5 4.1 Dosing Considerations ....................................................................................... 5 4.2 Recommended Dose and Preberite celoten dokument